Create Free Account

By creating account you will get access to hot stocks & personalised emails

Tissue Repair Ltd

Healthcare AU TRP

0.245AUD
-0.005(2.00%)

Last update at 2024-05-01T05:21:00Z

Day Range

0.230.24
LowHigh

52 Week Range

0.210.35
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -4.17441M -6.83759M -0.91523M -0.50087M -0.55515M
Minority interest - - - - -
Net income -4.17441M -6.83759M -0.91523M -0.35221M -0.35719M
Selling general administrative 1.18M 1.87M 0.06M 0.07M 0.02M
Selling and marketing expenses - - - - -
Gross profit 0.00308M - - - -
Reconciled depreciation 0.00265M 0.00171M - - -
Ebit -4.77175M -6.83759M -0.48853M -0.44856M -
Ebitda -5.73768M -6.83587M - - -
Depreciation and amortization - 0.00171M - - -
Non operating income net other - - - - -
Operating income -4.77175M -6.83759M -0.55337M -0.50090M -0.55722M
Other operating expenses - 5.45M - - -
Interest expense - 0.00000M - - -
Tax provision 0.00000M 0.00000M 0.00000M -0.14865M -0.19795M
Interest income 0.60M 0.04M 0.36M 0.00004M 0.00208M
Net interest income 0.43M 0.04M - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -1.42871M - -0.14865M -
Total revenue 0.00308M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses - 5.45M - - -
Cost of revenue - - - - -
Total other income expense net 1.14M -1.42871M - - -
Discontinued operations - - - - -
Net income from continuing ops -4.17441M -6.83759M - - -
Net income applicable to common shares -4.17441M -6.83759M -0.91523M -0.35221M -0.35719M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 22.38M 25.90M 27.61M 1.33M
Intangible assets - - - -
Earning assets - - - -
Other current assets 0.02M 0.06M 0.00500M 0.01M
Total liab 0.50M 0.56M 0.54M 0.33M
Total stockholder equity 21.88M 25.34M 27.07M 1.00M
Deferred long term liab - - - -
Other current liab 0.03M 0.36M 0.00200M -
Common stock 35.04M 35.04M 33.06M 3.85M
Capital stock 35.04M 35.04M 33.06M -
Retained earnings -14.80408M -10.62967M -6.05100M -2.87685M
Other liab 0.00655M 0.00086M - -
Good will - - - -
Other assets - - - 0.00500M
Cash 21.40M 25.46M 27.11M 1.15M
Cash and equivalents - - - -
Total current liabilities 0.49M 0.56M 0.54M 0.33M
Current deferred revenue - - - -
Net debt - -25.45529M -27.11100M -
Short term debt 0.00000M 0.00000M 0.00000M 0.00000M
Short long term debt - - - -
Short long term debt total - - - -
Other stockholder equity 1.65M 0.93M 0.06M 0.02M
Property plant equipment 0.00181M 0.00221M - -
Total current assets 22.38M 25.90M 27.61M 1.32M
Long term investments - - - -
Net tangible assets 21.88M 25.34M 0.09M 1.00M
Short term investments - - - -
Net receivables 0.83M 0.05M 0.05M 0.16M
Long term debt - 0.00000M 7.50M -
Inventory 0.02M - 0.44M -
Accounts payable 0.08M 0.20M 0.53M 0.33M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - 0.93M 0.06M -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 0.00181M 0.00221M 0.00000M -
Capital lease obligations - - - -
Long term debt total 0.00000M 0.00000M 7.50M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.00224M -0.00392M 0.00500M 0.00500M
Change to liabilities -0.10293M 0.01M 0.15M -0.35420M
Total cashflows from investing activities -0.00224M -0.00392M 0.00500M 0.00500M
Net borrowings - - 7.50M 7.50M
Total cash from financing activities 0.00000M 21.36M 7.46M 1.20M
Change to operating activities -0.02772M -0.07526M 0.00872M -0.00155M
Net income -4.17441M -6.83759M -0.91523M -0.35221M
Change in cash -4.05883M 17.69M 6.62M 0.55M
Begin period cash flow 25.46M 7.76M - -
End period cash flow 21.40M 25.46M 7.76M -
Total cash from operating activities -4.25546M -3.96615M -0.85289M -0.64998M
Issuance of capital stock - 22.00M - -
Depreciation 0.00265M 0.00171M 0.00171M 0.00171M
Other cashflows from investing activities - 0.00000M 0.00500M -
Dividends paid - - - -
Change to inventory -0.02029M -0.02029M -0.02029M -0.02029M
Change to account receivables -0.45203M 0.00616M -0.17336M 0.04M
Sale purchase of stock 0.00000M -0.63884M 0.00000M 1.20M
Other cashflows from financing activities 0.00000M -0.00392M -0.03507M -0.03507M
Change to netincome 0.52M 2.93M 0.07M 0.02M
Capital expenditures 0.00224M 0.00392M 0.00392M 0.00392M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital 0.42M 0.01M 0.00118M 0.00016M
Stock based compensation - - - -
Other non cash items - - - -
Free cash flow -4.25770M -0.00392M - -

Fundamentals

  • Previous Close 0.25
  • Market Cap14.81M
  • Volume27149
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.91901M
  • Revenue TTM1.03M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 0.97M
  • Diluted EPS TTM-0.06

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TRP
Tissue Repair Ltd		 -0.005 2.00% 0.24 - - 12.91 0.67 - 1.22
CSL
CSL Ltd		 0.90 0.33% 275.39 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.13 0.89% 14.80 748.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 0.12 0.63% 19.18 15.98 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.03 2.73% 1.07 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.

Tissue Repair Ltd

255 Pitt Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Tony Charara Co-Founder & Exec. Director NA
Mr. Cameron Jones C.A. Chief Financial Officer NA
Dr. Darryl Reed Chief Operating Officer NA
Mr. Michael Austin Company Sec. NA
Ms. Priyamvada Sanjay Rasal Company Secretary NA
Mr. Tony Charara Co-Founder & Executive Director NA
Mr. Tony Charara Co-Founder & Executive Director NA
Mr. Tony Charara Co-Founder & Executive Director NA
Ms. Priyamvada Sanjay Rasal Company Secretary NA
Mr. Tony Charara Co-Founder & Executive Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.